- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03230370
Does the Enhanced Rehabilitation Programs Facilitate the Motor Recovery After Stroke?
Does the Enhanced Rehabilitation Programs Facilitate the Motor Recovery After Stroke? A Multicenter Randomized Controlled Study (TIARAS Trial)
Study purpose This study will explore whether an additional rehabilitation program that focus on either upper or lower extremity training facilitate the recovery in upper or lower extremity.
The recovery in both neurological status and motor functions will be explored.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Design A single-blinded (assessor-blinded) randomized controlled trial. Interventions The participants will be randomly assigned into two experiment groups (enhanced upper extremity program; and enhanced lower-extremity program).
Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.
The enhanced upper extremity program group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity, while the enhanced lower-extremity program group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity. The participants receive 20-day training over a 4-week period. The additional program is designed to be specific to either upper-extremity or lower-extremity. Accordingly, one group can be used as the control group of the other one.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
New Taipei City, Taiwan
- WanFang Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- First-ever stroke with the onset 10-90 days prior to the enrollment
- Age: 20-80y
- With a hemiplegic upper extremity with Brunnstrom stage in I~IV
- Able to understand simple orders (1-step orders, such as "raise your hand, touch your head….)
- Totally independent in activity of daily life before the onset of stroke
Exclusion Criteria:
- Incompliance to the assessments or interventions due to unstable medical condition, abnormal cognition, or other conditions.
- Stroke of brainstem or cerebellum
- Had received craniotomy or ventriculoperitoneal shunting
- Needs of orthoses in walking before the onset of stroke
- Had had motor dysfunctions (eg, amputation, cerebral palsy, poliomyelitis or other neuromuscular diseases) before the stroke.
- Intracranial hemorrhage caused by artereovenous malformation, aneurysm, or tumor
- Able to walk independently for more than 50 meters.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: enhanced upper-extremity program, EUEP
Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy. The EUP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity. The participants receive 20-day training over a 4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity. Accordingly, one group can be used as the control group of the other one. |
The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,
|
Experimental: enhanced lower-extremity program,ELLP)
Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy. The ELP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity. The participants receive 20-day training over a4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity. Accordingly,one group can be used as the control group of the other one. |
The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fugl-Meyer Assessment (upper extremity subscale)
Time Frame: 0-, 4- week
|
The primary outcome is the change from baseline upper extremity subscale of Fugl-Meyer assessment at the end to 4-wk (post-intervention).
|
0-, 4- week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Action Research Arm Test (ARAT)
Time Frame: 0-, 4-, 8-, 12-, 24 week
|
A test that measures the upper extremity motor functions after the stroke.
|
0-, 4-, 8-, 12-, 24 week
|
Berg Balance Test
Time Frame: 0-, 4-, 8-, 12-, 24 week
|
A test that measures the balance functions.
|
0-, 4-, 8-, 12-, 24 week
|
Fugl-Meyer Assessment (lower extremity subscale)
Time Frame: 0-, 4-, 8-, 12-, 24 week
|
The FMA-LE (0-34) measures the lower extremity motor functions after the stroke.
|
0-, 4-, 8-, 12-, 24 week
|
Fugl-Meyer Assessment (upper extremity subscale)
Time Frame: 0-, 4-, 8-, 12-, 24 week
|
FMA-UE (0-66), the subscale of FMA that measures the poststroke neuro-motor functions.
|
0-, 4-, 8-, 12-, 24 week
|
Time required for 10 meter walking
Time Frame: 0-, 4-, 8-, 12-, 24 week
|
measuring the walking speed over a 10-meter distance
|
0-, 4-, 8-, 12-, 24 week
|
Stroke Impact Scale
Time Frame: 0-, 4-, 8-, 12-, 24 week
|
A measure for stroke-specific quality of life
|
0-, 4-, 8-, 12-, 24 week
|
Barthel Index
Time Frame: 0-, 4-, 8-, 12-, 24 week
|
to measure the activity of daily living
|
0-, 4-, 8-, 12-, 24 week
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- N201705071
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Poststroke/CVA Hemiparesis
-
Pamukkale UniversityCompletedSatisfaction, Patient | Hemiparesis;Poststroke/CVATurkey
-
Reuth Rehabilitation HospitalUniversity of HaifaTerminatedHemiparesis;Poststroke/CVAIsrael
-
University of IdahoUniversity of California, IrvineNot yet recruitingHemiparesis; Poststroke/CVA
-
University of HaifaReuth Rehabilitation HospitalRecruitingHemiparesis;Poststroke/CVAIsrael
-
UGECAM Rhône-AlpesRecruitingHemiparesis;Poststroke/CVAFrance
-
Loma Linda UniversityRecruitingHemiparesis;Poststroke/CVAUnited States
-
Reuth Rehabilitation HospitalUniversity of HaifaRecruitingHemiparesis;Poststroke/CVAIsrael
-
Clinique Du Parc de BellevilleHenri Mondor University HospitalRecruitingHemiparesis;Poststroke/CVAFrance
-
Centre for Interdisciplinary Research in Rehabilitation...CompletedHemiparesis;Poststroke/CVA
-
ThuasneUniversity Hospital of Saint-EtienneCompletedGait, Hemiplegic | Hemiparesis;Poststroke/CVAFrance
Clinical Trials on UFT
-
Association Européenne de Recherche en OncologieBristol-Myers SquibbUnknown
-
Tokyo UniversityHuman Genome Center, Institute of Medical Science, University of TokyoTerminatedColorectal Cancer | Rectal Cancer | Colon CancerJapan
-
Royal Marsden NHS Foundation TrustMerck Serono International SATerminated
-
Aromtech Ltd.The Finnish Funding Agency for Technology and InnovationCompleted
-
Iwate Medical UniversityUnknown
-
Edelman, Martin, M.D.Bristol-Myers SquibbUnknownEsophageal NeoplasmUnited States
-
Fudan UniversityCompletedGastric Cancer
-
Taiho Pharmaceutical Co., Ltd.Completed
-
Taiho Pharmaceutical Co., Ltd.Completed
-
Haruhiko FukudaMinistry of Health, Labour and Welfare, JapanCompletedColorectal NeoplasmsJapan